J. Randolph Hecht, MD

Randy Hecht, MD

Professor of Clinical Medicine, Department of Medicine, Hematology/Oncology, Gastrointestinal Oncology
Director, UCLA Gastrointestinal Oncology Program




Cancer/Medical Oncology, Gastroenterology/Digestive Diseases

Institutional Affiliation

Ronald Reagan UCLA Medical Center



Medical Oncology, UCLA School of Medicine, 1995 - 1997
Gastroenterology, UCLA School of Medicine, 1988 - 1991


Internal Medicine, Northwestern University Medical School, 1984 - 1985


MD, Eastern Virginia Medical School, 1984


Internal Medicine, Northwestern University Medical School, 1985 - 1987

Board Certifications

Medical Oncology, American Board of Internal Medicine, 1998
Gastroenterology, American Board of Internal Medicine, 1991
Internal Medicine, American Board of Internal Medicine, 1987

Contact Information

Clinical Interests

Cancers of the Digestive Tract

Scientific Interests

Dr. Randy Hecht's research and clinical interests concern malignancies of the gastrointestinal tract. He participates in a range of activities and is particularly interested in translating laboratory findings into improved patient care.

Hecht's current research includes preclinical models of therapy with biological agents, novel imaging techniques, Phase I studies with gene therapy vectors and tyrosine kinase inhibitors and leading large clinical trials evaluating inhibitors of angiogenesis and the epidermal growth factor receptor.

Highlighted Publications

Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012 Jun 28;486(7404):537-40.

Hecht JR, Farrell JJ, Senzer N, Nemunaitis J, Rosemurgy A, Chung T, Hanna N, Chang KJ, Javle M, Posner M, Waxman I, Reid A, Erickson R, Canto M, Chak A, Blatner G, Kovacevic M, Thornton M. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. Gastrointest Endosc. 2012 Feb;75(2):332-8.

Hecht JR, Trarbach T, Hainsworth JD, Major P, Jager E, Wolff RA, Lloyd-Salvant K, Bodoky G, Pendergrass K, Berg W, Chen BL, Jalava T, Meinhardt G, Laurent D, Lebwohl D, Kerr D. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol. 2011 May 20;29(15):1997-2003. Epub 2011 Apr 4

Hecht JR, Mitchell E, Neubauer MA, Burris HA, Swanson P, Lopez T, Buchanan G, Reiner M, Gansert J, Berlin J. Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res. 2010 Apr 1;16(7):2205-13. Epub 2010 Mar 23

Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009 Feb 10;27(5):672-80. Epub 2008 Dec 29